Basilea News Basilea News en Thu, 29 Jun 2017 16:19:18 +0200 Thu, 29 Jun 2017 16:19:18 +0200 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey and Israel]]>
  • Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
  • Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
  • Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio

  • ]]>
    Wed, 14 Jun 2017 19:15:00 +0200
    <![CDATA[Basilea announces distribution agreement with Avir Pharma Inc. for Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) in Canada]]> Wed, 14 Jun 2017 07:15:00 +0200 <![CDATA[Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole]]> Tue, 13 Jun 2017 07:15:00 +0200 <![CDATA[Basilea announces clinical study agreement with Adult Brain Tumor Consortium to explore BAL101553 in newly diagnosed glioblastoma]]>
  • The Adult Brain Tumor Consortium (ABTC) is designed to develop more effective treatments for malignant brain tumors. It is funded by the US National Cancer Institute (NCI).
  • The ABTC will conduct a clinical phase 1 study to determine the safety and tolerability of Basilea's novel tumor checkpoint controller BAL101553 in newly diagnosed glioblastoma patients.
  • ]]>
    Mon, 12 Jun 2017 07:15:00 +0200
    <![CDATA[Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting]]> Tue, 06 Jun 2017 07:15:00 +0200 <![CDATA[Basilea names new member of its Extended Management Committee]]> Fri, 02 Jun 2017 07:15:00 +0200 <![CDATA[Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders]]> Thu, 27 Apr 2017 18:31:45 +0200 <![CDATA[Basilea announces agreement with FDA on Special Protocol Assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections]]>
  • Initiation of ceftobiprole pivotal phase 3 clinical program under BARDA contract anticipated within the next three to six months
  • ]]>
    Fri, 21 Apr 2017 07:15:00 +0200
    <![CDATA[Data presented at AACR meeting indicate diverse tumor-targeting properties of Basilea's BAL101553 and show a combination potential with bevacizumab]]>
  • BAL101553 targets tumor cell proliferation, adaptation to low oxygen and vascularization
  • Switch from weekly to daily oral dosing leads to reduced tumor anti-vascular activity while maintaining tumor growth inhibition
  • Combination with the anti-VEGF therapy bevacizumab shows enhanced anti-tumor response
  • ]]>
    Thu, 06 Apr 2017 07:15:00 +0200
    <![CDATA[Basilea proposes Dr. Nicole Onetto as new member of the Board of Directors]]> Mon, 27 Feb 2017 07:15:00 +0100